BofA/Merrill Lynch maintained a Buy rating on bluebird bio (NASDAQ: BLUE) but lowered its price target to $149.00 (from $241.00). Analyst Ying Huang reduced the addressable market for BB305 to 50% in severe thalassemia patients ineligible for stem cell transplant and lowered approval probability to 42% following recent data.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $70.36 yesterday.

Analyst Comments Analyst PT Change

Too Earlier to Write Off bluebird bio's (BLUE) LentiGlobin in Subset - CowenNovember 5, 2015 3:44 PM bluebird bio (BLUE) LentiGlobin is Here To Stay, Roth Capital Says; PT Cut to $165November 5, 2015 1:27 PM bluebird bio (BLUE) LentiGlobin 'Does Work', Maxim Group SaysNovember 5, 2015 1:06 PM bluebird bio (BLUE) Most Severe Beta-Thal Patients Presenting Challenges, Wedbush Comments; PT Lowered to $165November 5, 2015 12:39 PM 'Not Time to Hit Panic Button' on bluebird bio (BLUE), Oppenheimer SaysNovember 5, 2015 12:23 PM bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH UpdateNovember 5, 2015 8:20 AM bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of HematologyNovember 5, 2015 8:00 AM